Chaitra Ujjani, MD, Oncology, Seattle, WA, Seattle Cancer Care Alliance

ChaitraShankarUjjaniMD

Oncology Seattle, WA

Hematologic Oncology

Assistant Professor, Medicine, Georgetown University School of Medicine

Overview of Dr. Ujjani

Dr. Chaitra Ujjani is an oncologist in Seattle, WA and is affiliated with Seattle Cancer Care Alliance. She received her medical degree from University of Alabama School of Medicine and has been in practice 12 years. Dr. Ujjani accepts several types of health insurance, listed below. She is one of 147 doctors at Seattle Cancer Care Alliance who specialize in Oncology.

Education & Training

  • Georgetown University Hospital
    Georgetown University HospitalFellowship, Hematology/Oncology, 2008 - 2011
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 2005 - 2008
  • University of Alabama School of Medicine
    University of Alabama School of MedicineClass of 2005

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2018 - 2023
  • DC State Medical License
    DC State Medical License 2008 - 2018
  • PA State Medical License
    PA State Medical License 2005 - 2008
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Real World Outcomes and Management Strategies for Venetoclax-Treated Chronic Lymphocytic Leukemia Patients in the United States  
    Arun K Singavi, Andrew Zelenetz, Nicole Lamanna, Bruce D Cheson, Richard R Furman, Jakub Svoboda, Stephen J Schuster, John N Allan, Chaitra S Ujjani, Haematologica

Abstracts/Posters

  • CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas
    Chaitra S. Ujjani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas
    Chaitra S. Ujjani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL...
    Chaitra S. Ujjani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • Axi-Cel Moves Toward the First-Line Setting for High-Risk Large B-cell Lymphoma
    Axi-Cel Moves Toward the First-Line Setting for High-Risk Large B-cell LymphomaAugust 5th, 2019
  • Expert Roundtable: Lessons from ASH for Optimizing CLL Treatment
    Expert Roundtable: Lessons from ASH for Optimizing CLL TreatmentDecember 21st, 2018
  • The High-Risk Group for Whom Covid-19 Vaccines May Not Work Effectively
    The High-Risk Group for Whom Covid-19 Vaccines May Not Work EffectivelyApril 21st, 2021

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    Anthem KeyCare PPO
    BCBS Blue Card PPO
    BCBS Tennessee Network 5
    Multiplan PHCS PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment